Evenity Romosozumab Injection

Evenity Romosozumab Injection

Therapeutic Class: Pain Analgesics
Get Quote

Evenity Romosozumab Injection contains the active ingredient Romosozumab, a humanized monoclonal antibody that promotes bone formation while simultaneously inhibiting bone resorption. It belongs to the anti-osteoporotic agents class and is primarily indicated for the treatment of osteoporosis in postmenopausal women who are at high risk of fractures. By increasing bone mineral density and strength, Injection Evenity reduces the risk of both vertebral and non-vertebral fractures in patients with severe osteoporosis. This treatment is particularly recommended for individuals who have not responded well to other osteoporosis therapies.

Evenity Injection uses include reducing the likelihood of fractures in postmenopausal women who have experienced multiple fractures or are at risk due to significantly low bone mass. It is administered as a subcutaneous injection once a month for 12 months. Evenity injection dose is typically 210 mg per month, provided as two consecutive injections. Patients are usually transitioned to anti-resorptive therapy following the completion of the 12-month course to maintain the benefits gained.

Although effective, it is essential to be aware of Evenity injection side effects, which may include joint pain, headache, injection site reactions, and, in rare cases, an increased risk of cardiovascular events. Patients with a history of heart attack or stroke should avoid this medication. Evenity injection instructions must be followed carefully to minimize potential adverse effects. It is advised to monitor calcium and vitamin D levels during treatment to prevent hypocalcemia.

For those considering this treatment, Evenity injection reviews highlight its effectiveness in improving bone density and reducing fractures. However, it is essential to consult a healthcare provider to assess individual risks and benefits, as the cost of Evenity injection can be high.

Salt Composition: Romosozumab (105mg)
Strength: Romosozumab (105mg)
Pack Size: 1.17 ml in 1 prefilled syringe
Uses: Treatment of osteoporosis in postmenopausal women at high risk of fracture I Reducing the incidence of vertebral and non-vertebral fractures
Table Header
Salt Composition
Romosozumab (105mg)
Strength
Romosozumab (105mg)
Pack Size
1.17 ml in 1 prefilled syringe
Uses
Treatment of osteoporosis in postmenopausal women at high risk of fracture I Reducing the incidence of vertebral and non-vertebral fractures
DISCLAIMER
N Chimanlal Enterprises (www.pilcare.com) is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India. Product is supplied for Tenders/ Emergency imports/ Unlicensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials. Product names, logos, brands and other trademarks featured or referred to are the property of their respective Trademark Holders. The information provided here is for Informational purposes only.

Product information is meant for


WholesalersSuppliersExportersDoctorsMOH Tender SuppliesHospitalsBrandCROsComparator SuppliesGenericCooperate SourcingIndividual PatientsIndian Institutional Buyers
Recently Viewed
Categories